Tucuvi vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Tucuvi's LOLA is the first EU Class IIb certified AI medical voice agent; in 60+ health systems with $20M Series A, running post-discharge follow-ups and chronic care check-ins (Jan 2026).
About
Tucuvi is a Spanish clinical AI company that has developed LOLA, a conversational voice AI agent for healthcare. LOLA conducts automated clinical conversations with patients — including post-discharge follow-ups, chronic disease monitoring check-ins, pre-appointment screenings, and medication adherence calls — with the tone, clinical accuracy, and empathy expected of a skilled nurse or care coordinator. Tucuvi was founded by a team combining clinical expertise and AI engineering to address the growing gap between care demand and available clinical staff in European health systems.\n\nThe LOLA platform integrates with hospital information systems and electronic health records, enabling health systems to deploy automated voice interactions at scale across their patient populations. The system is multilingual and capable of conducting clinically meaningful conversations that capture structured data, flag deteriorating patients, and escalate to human clinicians when needed. Unlike general-purpose voice assistants, LOLA is specifically trained on clinical language, patient interaction patterns, and healthcare workflows.\n\nTucuvi achieved a landmark regulatory milestone by becoming the first EU Class IIb certified AI medical device in the voice AI category, a certification level that covers devices posing moderate to high risk — the same classification as many implantable devices. This certification is a significant commercial differentiator in Europe's tightly regulated healthcare market. The company raised a $20M Series A, serves 60+ health systems, and has conducted 300,000+ clinical voice calls. Its 2025–2026 momentum reflects growing European health system interest in AI that can extend care capacity without adding nursing headcount.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.